Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine

References

• Rappuoli R, Miller, HI, Falkow S. Medicine. The intangible value of vaccination. Science297, 937–939 (2002).
   PubMed Web of Science ®Google Scholar
• Deepe GS. Preventative and therapeutic vaccines for fungal infections: from concept to implementation. Expert Rev. Vaccines3, 701–709 (2004).
   PubMedGoogle Scholar
• Deepe GS Jr, Wuthrich M, Klein BS. Progress in vaccination for histoplasmosis and blastomycosis: coping with cellular immunity. Med. Mycol.43, 381–389 (2005).
   PubMed Web of Science ®Google Scholar
• Casadevall A, Feldmesser M, Pirofski LA. Induced humoral immunità and vaccination against major human fungal pathogens. Curr. Opin. Microbiol.5, 386–391 (2002).
   PubMed Web of Science ®Google Scholar
• Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for fungal infections. Nat. Rev. Microbiol.2, 695–703 (2004).
   PubMed Web of Science ®Google Scholar
• Cox RA, Magee DM. Coccidioidomycosis: host response and vaccine development. Clin. Microbiol. Rev.17, 804–839 (2004).
   PubMed Web of Science ®Google Scholar
• Feldmesser M. Prospects of vaccines for invasive aspergillosis. Med. Mycol.3, 571–587 (2005).
   Google Scholar
• Mochon BA, Cutler E. Is a vaccine needed against Candida albicans? Med. Mycol.43, 97–115 (2005).
   PubMed Web of Science ®Google Scholar
• Suligoi B, Borros S, Camoni L, Lepore D. Aggiornamento dei casi di Aids notificati in Italia al 30 giugno 2005. Notiziario ISS18(Suppl. 1), 3–19 (2005).
   Google Scholar
• Stevens DA. Vaccinate against aspergillosis! A call to arms of the immune system. Clin. Infect. Immun.38, 1131–1136 (2004).
   PubMed Web of Science ®Google Scholar
• Sheppard DC, Edwards JE Jr. Development of a vaccine for invasive aspergillosis. Clin. Infect. Dis.38, 1137–1138 (2004).
   PubMed Web of Science ®Google Scholar
• Sims CR, Ostrosky-Zeichner L, Rex JH. Invasive candidiasis in immunocompromised hospitalized patients. Arch. Med. Res.36, 660–671 (2005).
   PubMed Web of Science ®Google Scholar
• Sobel JD, Wisenfeld, HC, Martens M et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N. Eng. J. Med.351, 876–883 (2004).
   PubMed Web of Science ®Google Scholar
• Wormley FL Jr, Cutright JL, Fidel PL Jr. Multiple experimental designs to evaluate the role of T cell-mediated immunity against experimental vaginal Candida albicans infection. Med. Mycol.41, 401–410 (2001).
   Web of Science ®Google Scholar
• Plotkin S, Orenstein WA. Vaccines. Saunders, PA, USA (1999).
   Google Scholar
• Matthews RC, Burnie JP. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine22, 865–871 (2004).
   PubMed Web of Science ®Google Scholar
• Matthews RC, Rigg G, Hodgetts S et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother.47, 2208–2216 (2003).
   PubMed Web of Science ®Google Scholar
• Bromuro C, Torosantucci A, Chiani P et al. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun.70, 5462–5470 (2002).
   PubMed Web of Science ®Google Scholar
• Torres M, May R, Scharff MD, Casadevall A. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J. Immunol.174, 2132–2142 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang MX, Bohlman MC, Itatani et al. Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect. Immun.74, 362–369 (2006).
   PubMed Web of Science ®Google Scholar
• Xin H, Cutler JE. Hibridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis. Infect. Immun.74, 4310–4321 (2006).
   PubMed Web of Science ®Google Scholar
• De Bernardis F, Boccanera M, Adriani D et al. Intravaginal and intranasal immunization are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect. Immun.70, 2725–2729 (2002).
   PubMed Web of Science ®Google Scholar
• Vilanova M, Teixeira L, Caramalho I et al. Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunology111, 334–342 (2004).
   PubMed Web of Science ®Google Scholar
• Latgè JP, Calderone R. Host–microbe interactions: fungi invasive human fungal opportunistic infections. Curr. Opin. Microbiol.5, 355–358 (2002).
   PubMed Web of Science ®Google Scholar
• Chandra J, Kuhn DM, Muckerjee PK et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture and drug resistance. J. Bacteriol.183, 5385–5394 (2001).
   PubMed Web of Science ®Google Scholar
• De Bernardis F, Liu H, O’Mahony R et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J. Infect. Dis.195, 149–157 (2007).
   PubMed Web of Science ®Google Scholar
• Martinez LR, Casadevall A. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect. Immun.73, 6350–6362 (2005).
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. Polysaccharide-containing conjugate vaccines for fungal diseases. Trends Mol. Med.12, 6–9 (2006).
   PubMed Web of Science ®Google Scholar
• Monari C, Kozel TR, Paganelli F et al. Microbial immunosuppression mediated by direct engagement of inhibitory Fc receptor. J. Immunol.177(10), 6842–6851 (2006).
   PubMed Web of Science ®Google Scholar
• Kawishar A, Shuckla PK. Candidacidal activity of a monoclonal antibody that binds with glycosyl moieties of proteins of Candida albicans. Med. Mycol.44, 159–167 (2006).
   PubMed Web of Science ®Google Scholar
• Magliani W, Conti S, Salati et al. Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr. Med. Chem.11, 1793–1800 (2004).
   PubMed Web of Science ®Google Scholar
• Cassone A, Conti S, De Bernardis F, Polonelli L. Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol. Today18, 164–169 (1997).
   PubMedGoogle Scholar
• Polonelli L, De Bernardis F, Conti S. et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory yeast killer toxin-like anti-idiotype antibodies. J. Immunol.152, 3175–3182 (1994).
   PubMed Web of Science ®Google Scholar
• Polonelli L, Lorenzini R, Gerloni M et al. Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scand. J. Immunol.37, 105–110 (1993).
   PubMed Web of Science ®Google Scholar
• Moragues MD, Omaxtebarria MJ, Elguezabal MJ et al. A monoclonal antibody directed against Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect. Immun.71, 5273–5279 (2003).
   PubMed Web of Science ®Google Scholar
• Selvakumar D, Miyamoto M, Furuichi Y, Komiyama T. Inhibition of fungal β-1–3 glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies. Antimicrob. Agents Chemother.50, 3090–3097 (2006).
   PubMed Web of Science ®Google Scholar
• Torosantucci A, Bromuro C, Chiani P et al. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med.202, 597–606 (2005).
   PubMed Web of Science ®Google Scholar
• Brown GD, Gordon S Fungal β-glucans and mammalian immunity. Immunity19, 311–315 (2003).
   PubMed Web of Science ®Google Scholar
• Cassone A, Torosantucci A. Candida albicans. Springer-Verlag, Berlin Heidelberg, Germany (1991).
   Google Scholar
• Klis FM, de Groot P, Hellingwerf K. Molecular organization of the cell wall of Candida albicans. Med. Mycol.39, 1–8 (2001).
   PubMed Web of Science ®Google Scholar
• Masuoka J. Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses and experimental challenges. Clin. Microbiol. Rev.17, 281–310 (2004).
   PubMed Web of Science ®Google Scholar
• Chaffin WL, Lopez-Ribot JL, Casanova M, et al. Cell wall and secreted proteins of Candida albicans: identification, function and expression. Microbiol. Mol. Biol. Rev.62, 130–80 (1998).
   PubMed Web of Science ®Google Scholar
• Luther K, Torosantucci A, Brakhage AA et al. Phagocytosis of Aspergillus fumigatus conidia by murine macrophages involves recognition by detection β-glucan receptor and Toll-like receptor 2. Cell. Microbiol. (2006) (In press).
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Spellberg BJ, Avenissian V et al. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun.73, 999–1005 (2005).
   PubMed Web of Science ®Google Scholar
• Kumamoto CA, Vinces MD. Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence. Cell. Microbiol.7, 1546–54 (2005).
   PubMed Web of Science ®Google Scholar
• Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog.2, 328–337 (2006).
   Web of Science ®Google Scholar
• Romani L, Mencacci A, Cenci E et al. CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J. Immunol.150, 925–931 (1993).
   PubMed Web of Science ®Google Scholar
• Gartner BN, Simmons RM, Underhill DM. Dectin-1 mediates macrophage recognition of Candida albicans yeasts but not filaments. EMBO J.24, 1277–1286 (2005).
   PubMed Web of Science ®Google Scholar
• Ishibashi K, Yoshida M, Nakabayashi I, et al. Role of anti-β-glucan antibodies in host defense against fungi. FEMS Immunol. Med. Microbiol.44, 99–109 (2005).
   PubMedGoogle Scholar
• Bozza S, Montagnoli C, Gaziano R et al. Dendritic cell-based vaccination against opportunistic fungi. Vaccine22, 857–864 (2004).
   PubMed Web of Science ®Google Scholar
• Traggiai E, Becker S, Subbarao K et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med.10, 871–875 (2004).
   PubMed Web of Science ®Google Scholar
• Hudson PJ, Soriau C. Engineered antibodies. Nat. Med.9, 129–134 (2003).
   PubMed Web of Science ®Google Scholar
• Han Y, Morrison RP, Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infections. Infect. Immun.60, 5771–5776 (1998).
   Google Scholar
• Han Y, Ulrich MA, Cutler JE. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J. Infect. Dis.179, 1477–1484 (1999).
   PubMed Web of Science ®Google Scholar
• Levy R, Segal E, Eylan E. Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fraction. Infect. Immun.31, 874–878 (1981).
   PubMed Web of Science ®Google Scholar
• Cardenas-Freitag L, Cheng E, Mayeux P et al. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect. Immun.67, 826–833 (1999).
   PubMed Web of Science ®Google Scholar
• Tavares D, Ferreire P, Vilanova M et al. Immunoprotection against systemic candidiasis in mice. Int. Immunol.7, 785–796 (1995).
   PubMed Web of Science ®Google Scholar
• Bacci A, Montagnoli C, Perruccio K et al. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J. Immunol.168, 2904–2913 (2002).
   PubMed Web of Science ®Google Scholar
• Segal E, Elad D. Fungal vaccines and immunotherapy. Journal de Mycologie Medicale16, 134–151 (2006).
   Web of Science ®Google Scholar